Skip to content

Quick ratio at other companies

Baxter International logo
Baxter InternationalBAX
1.2×-0.2×
Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
1.2×-0.2×
ADMA Biologics logo
ADMA BiologicsADMA
3.9×+0.6×
Medpace Holdings, Inc. logo
Medpace Holdings, Inc.MEDP
0.8×+0.1×
Biodesix, Inc. logo
Biodesix, Inc.BDSX
2.8×+0.6×
ClearPoint Neuro logo
ClearPoint NeuroCLPT
4.9×+1.4×

Other financials

Income statement

See full
Revenue$23.2M-36.4%
Gross profit$4.5M-68.1%
Operating income-$4.7M
Net income-$15.0M-1,206%
EPS (diluted)-$0.43-1,333%

Balance sheet

See full
Cash & equivalents$20.8M+152%
Total debt$156.9M+1,310%
Total equity-$28.4M-2,229%
Total assets$225.5M-5.8%

Cash flow

See full
Operating cash flow$4.7M
CapEx$1.1M-46.7%
Free cash flow$3.6M

Valuation

See full
Market cap$196.92M-35.4%
Enterprise value$333.06M+8.3%
P/S1.6×+0.5×

Profitability

See full
Gross margin31.3%-1.4pp
Operating margin-14.5%-2.2pp
Net margin-30%
FCF margin-36.4%

Returns & leverage

See full
Return on equity-612.1%
Debt / equity8.3×-1.5×
Current ratio3.8×+0.9×

Where this comes from

Calculated from Lifecore Biomedical, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Lifecore Biomedical, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Lifecore Biomedical, Inc.'s quick ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Lifecore Biomedical, Inc.'s quick ratio?
Lifecore Biomedical, Inc. (LFCR) reported quick ratio of 2.4× in Q1 2026.
How has Lifecore Biomedical, Inc.'s quick ratio changed year-over-year?
Lifecore Biomedical, Inc.'s quick ratio increased by 36.5% year-over-year, from 1.8× to 2.4×.
What is the long-term trend for Lifecore Biomedical, Inc.'s quick ratio?
Over 5 years (2021 to 2026), Lifecore Biomedical, Inc.'s quick ratio has grown at a 17.2% compound annual growth rate (CAGR), from 1.1× to 2.4×.
What does quick ratio mean?
Current assets excluding inventory, divided by current liabilities at the quarter end (the 'acid-test'). A stricter liquidity measure that excludes the least-liquid current asset.